← Back to headlines
Stifel Says Fulcrum Therapeutics Stock Drop 'Overdone'
Stifel analysts believe that the recent decline in Fulcrum Therapeutics' stock price is 'overdone,' suggesting an overreaction by the market.
25 Feb, 15:27 — 25 Feb, 15:27
ℹOnly 1 source covers this story
Read at source (1 outlet)
Related Stories
Nigeria Deposit Insurance Corporation (NDIC) Reports 2025 Budget Execution and 2026 Proposal
just now
HELLENiQ ENERGY Reports Strong 2025 Financial Results
11m ago
Chemed cut to Neutral at BofA after Q4 miss
14m ago
Athens Stock Exchange: 12 Blue Chips Defy Correction and Continue Record Performance
17m ago